EyePoint制药公司(EYPT)在10月29日盘中出现大幅下跌,股价一度大跌8.09%,引发了市场的广泛关注。
导致该公司股价下跌的主要原因是,EyePoint宣布公开发行价值1亿美元的新股。此举将增加公司股票供应量,导致现有股东权益遭到进一步稀释,因此引发了投资者的担忧情绪。消息公布后,股价在盘后一度下挫8.5%,最低跌至11.09美元。
不过,EyePoint表示将利用此次发行所得资金继续推进其糖尿病黄斑水肿药物Duravyu的开发工作,并支持其他早期管线产品的研发。但这一利好消息似乎难以完全抵消新股发行导致股权稀释对股价的冲击。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.